Genprex Advances to Highest Dose Group in Acclaim-3 Trial for Reqorsa Gene Therapy in Combination with Tecentriq After Receiving Safety Review Committee Approval
Portfolio Pulse from Benzinga Newsdesk
Genprex has advanced to the highest dose group in its Acclaim-3 trial for Reqorsa gene therapy, in combination with Tecentriq, after receiving approval from the Safety Review Committee.
October 15, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex has received approval to advance to the highest dose group in its Acclaim-3 trial for Reqorsa gene therapy, in combination with Tecentriq. This marks a significant step in the trial's progress.
The advancement to the highest dose group in the Acclaim-3 trial indicates positive progress in the development of Reqorsa gene therapy. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100